ArticleBMC cancer2022
Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 43 citations in OpenAlex.
- From Machine Learning-Enhanced Proteomics to a Validated Diagnostic Model: A Pipeline for Breast Cancer Biomarker Discovery via Independent and Transcriptomic Corroboration.Bioengineering (Basel, Switzerland) · 2026Article
- Nano-biosensors for circulating tumor markers: advancing liquid biopsy toward precision cancer diagnostics.Journal of cancer research and clinical oncology · 2026Review
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer.Frontiers in oncology · 2026Article
- Periostin: A matricellular protein with a multifaceted role in tumorigenesis (Review).International journal of molecular medicine · 2025Review
- Decoding the mechanisms underlying breast cancer brain metastasis: paving the way for precision therapeutics.Biomarker research · 2025Review
- A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.Biomolecules · 2025Review
- A dual-signal-amplified electrochemical biosensor for sensitive and accurate detection of cancer cells.RSC advances · 2025Article
- Simultaneous detection of membrane protein and mRNA at single extracellular vesicle level by droplet microfluidics for cancer diagnosis.Journal of advanced research · 2025Article
- Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach.Breast cancer research : BCR · 2025Article
- Integrative Single-Cell and Spatial Transcriptomics Analysis Reveals ECM-remodeling Cancer-associated Fibroblast-Derived POSTN as a Key Mediator in Pancreatic Ductal Adenocarcinoma Progression.International journal of biological sciences · 2025Article
- Exploring research progress in studying serum exosomal miRNA-21 as a molecular diagnostic marker for breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024Review
- Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients.Journal of medical biochemistry · 2024Article
- Soluble Periostin is a potential surveillance biomarker for early and long-term response to chemotherapy in advanced breast cancer.Cancer cell international · 2024Article
- Serum Direct Bilirubin as a Biomarker for Breast Cancer.Breast cancer (Dove Medical Press) · 2024Article
- Predictive value of CA-153, CA-125 and Apo A for ocular metastasis in menopausal female patients with breast cancer.International journal of ophthalmology · 2024Article
- NIR-II fluorescent AgMikrochimica acta · 2023Article
- Assessment of the albumin-bilirubin score in breast cancer patients with liver metastasis after surgery.Heliyon · 2023Article
- The biomarkers related to immune infiltration to predict distant metastasis in breast cancer patients.Frontiers in genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BCa) is the leading cause of cancer deaths among women. Reliable biomarkers for early diagnosis and metastasis prediction are essential to improve the prognosis of BCa. This study aimed to evaluate serum periostin (POSTN) as a novel biomarker complementing CA153 (carbohydrate antigen 153) and CEA (carcinoembryonic antigen) for BCa diagnosis and metastasis prediction.
methodsTo assess the potential of soluble POSTN as a circulating biomarker, 242 participants, including 173 patients with different stages of BCa and 69 healthy individuals, were enrolled in this study. Soluble POSTN, together with CA153 and CEA, were determined in serum by enzyme linked immunosorbent assay (ELISA) or electrochemiluminescence immunoassays.
resultsSerum POSTN levels in locoregional BCa patients were significantly higher than that in healthy controls. Receiver operating curve (ROC) analysis revealed that, to distinguish health controls from locoregional BCa, POSTN was observed with the highest AUC (area under curve) (AUC
conclusionsThis study suggested that soluble POSTN is a promising potential biomarker for diagnosis and metastasis prediction of BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.